Infrared Imaging: A New Method for Grading Breast Cancer Biopsies

A Brief Overview of Current Systems for Assessing Breast Cancer Pathology (Grading)
Breast canceris among the world's most common cancers, and recent treatment advances have substantially reduced mortality. Clinicians nevertheless urgently need more accurate techniques to determine treatment requirements for diverse patients, particularly those with estrogen receptor (ER)-positive disease.
Estrogen receptor-positive cancers account for approximately 80% of breast cancers, and hormone therapy plus chemotherapy is their main medical treatment. Clinicians must nevertheless decide whether chemotherapy adds benefit for every hormone-positive patient, particularly early-stage patients with small tumors. One of the most important determinants is the breast tissue's grade measurement.
A cancer's gradedescribes tumor cell differentiation and the number of mitotic divisions, proportional to aggressiveness. Higher-grade tumors consist of less differentiated, more frequently dividing cells. Grades are generally numbered 1-4.
The most common histopathological (microscopic) diagnostic method is hematoxylin and eosin (H+E) staining. Visually graded sections require disease-specific protocols and rely on subjective criteria. For example, analyzing approximately 24.000 biopsies, 732 pathologists grading breast cancer tissue agreed on grade an average of 73% of the time.
The mid-infrared (mid-IR) electromagnetic spectrum covers wavelengths approximately from 2.5 µm to 25 µm. Molecules absorb these wavelengths linearly through vibronic transitions specific to chemical bonds, producing different molecule-specific fingerprint peaks. Infrared chemists have long used infrared light, often in automated systems, to analyze unknown mixtures' chemical composition and measure compound concentrations.
A New Approach to Breast Cancer Grading: Digistain
Scientists extended this technique through Digistain, measuring absorption of selected mid-infrared wavelengths in 2-dimensional images. The chosen 8 µm and 6 µm wavelengths are absorbed as vibrational excitations in phosphate (nuclear) and amide (cytoplasmic) components, respectively. Raw absorption data are processed into a spatial map of their ratio across a tissue section, with percentage-level precision. A computer colors the image accordingly. Using an H+E-stained breast cancer pathology block as reference, a pathologist selects a region of interest and averages corresponding pixel values in the Digistain tumor image to produce a percentage-level precise Digistain image score, the "DI score." It is then correlated with prior histopathological and clinical data.
The study found a strong correlation between the pathologist's grade and the infrared measurement, meaning the two results were consistent.
Digistain uses routinely processed but unstained paraffin blocks of cancer tissue and can determine the nuclear-cytoplasmic chemical ratio within minutes. Tumor grade is determined by this ratio: greater nuclear activity means a higher ratio and grade. Personnel without advanced training can perform the test with one mouse click. Its image data can be stored and transmitted digitally and analyzed through (Big Data) .
Future work may partially or completely automate grading because Digistain images are digital. The controlled, objective measurement means pixel values are absolute values directly related to the nuclear-cytoplasmic chemical ratio. This ratio itself is a known cancer biomarker. Such an "absolute value" property is unusual in biomedical imaging and will offer new avenues for future machine-vision image analysis.
Sources
Mid-infrared imaging in breast cancer tissue: an objective measure of grading breast cancer biopsies.
Convergent Science Physical Oncology, march 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.